IPP Bureau
Alniche Life Sciences launches #GutHealthAwareness campaign
By IPP Bureau - December 31, 2022
Having a healthy gut is key as it permits the body to build a stronger immune system
USFDA grants appeal for Ardelyx's XPHOZAH
By IPP Bureau - December 31, 2022
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
InnoCare get approval of Tafasitamab with Lenalidomide for the treatment of refractory diffuse large B-Cell lymphoma in Hong Kong
By IPP Bureau - December 31, 2022
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
USFDA accepts for review the biologics license application for Pfizer’s Investigational MenABCWY in adolescents
By IPP Bureau - December 31, 2022
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
Cipla EU to invest € 15 million in Ethris
By IPP Bureau - December 30, 2022
Cipla and Ethris partner for the development of mRNA-based therapies
Claim against Dr. Reddy’s Laboratories dismissed over Revlimid in US
By IPP Bureau - December 30, 2022
All claims against the company in the litigation have now been dismissed.
Samples taken from Marion Biotech Noida facility sent to RDTL, Chandigarh for testing
By IPP Bureau - December 30, 2022
There have been reports from Uzbekistan concerning contaminated cough syrup Dok1 Max made by Indian company Marion Biotech, Noida, Uttar Pradesh
Eye-Q inaugurates its new facility in Yamunanagar
By IPP Bureau - December 30, 2022
The new facility will be able to handle four times as many patients as the previous facility.
Mandaviya and Puri hail MoU between IndianOil and Central TB Division for states of UP and Chhattisgarh
By IPP Bureau - December 29, 2022
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
Stelis Biopharma’s CDMO partner receives approval for key ANDA from the USFDA
By IPP Bureau - December 29, 2022
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
Hester to develop low pathogenic avian influenza inactivated vaccine for poultry
By IPP Bureau - December 29, 2022
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
World's first intranasal vaccine iNCOVACC will be rolled out in the fourth week of January
By IPP Bureau - December 29, 2022
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
AIIMS organises consultation on ‘C2IQ’
By IPP Bureau - December 29, 2022
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
CDSCO and State Drugs Control Administration commence joint inspection of drug manufacturing units
By IPP Bureau - December 28, 2022
A committee of two Joint Drugs Controllers has been constituted at CDSCO to monitor the process of inspection, reporting, and subsequent action to ensure compliance to the Drugs & Cosmetics Act, 1940
